Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DMBQ10
|
|||
| Drug Name |
ABTL0812
|
|||
| Synonyms |
ABTL-0812; 57818-44-7; alpha-Hydroxylinoleic acid; ABTL0812; (alpha)-Hydroxylinoleic acid; 2-hydroxy-9Z,12Z-Octadecadienoic acid; (9Z,12Z)-2-hydroxyoctadeca-9,12-dienoic acid; 0DE74TJ7EZ; 9,12-Octadecadienoic acid, 2-hydroxy-, (9Z,12Z)-; (9Z,12Z)-2-Hydroxy-9,12-octadecadienoic acid; 9,12-Octadecadienoic acid, 2-hydroxy-, (Z,Z)-; hydroxylinoleic acid; a-Hydroxylinoleic acid; 2-hydroxylinoleic acid; UNII-0DE74TJ7EZ; SCHEMBL320069; CHEBI:136927; DTXSID301258077; .ALPHA.-HYDROXYLINOLEIC ACID; HY-U00141; LMFA02000290; s9611; AKOS040740632; CS-7178; (9Z,12Z)-2-hydroxyoctadecadienoic acid; MS-24253
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Pancreatic cancer [ICD-11: 2C10; ICD-9: 157] | Phase 1/2 | [1] | |
| Company |
Ability Pharmaceuticals Barcelona, Spain
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H32O3
|
|||
| Canonical SMILES |
CCCCCC=CCC=CCCCCCCC(C(=O)O)O
|
|||
| InChI |
InChI=1S/C18H32O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17(19)18(20)21/h6-7,9-10,17,19H,2-5,8,11-16H2,1H3,(H,20,21)/b7-6-,10-9-
|
|||
| InChIKey |
AFDSETGKYZMEEA-HZJYTTRNSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Peroxisome proliferator-activated receptor (PPAR) | Target Info | Agonist | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04431258) A Phase I Open Label Followed by a Phase II Randomized, Controlled Study to Assess the Efficacy and Safety of ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic. U.S.National Institutes of Health. | |||
| REF 2 | The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells. Autophagy. 2021 Jun;17(6):1349-1366. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.